| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P6179 | Dimensions Publication ID | 1109897569 |
| P356 | DOI | 10.1186/S13643-018-0854-Y |
| P932 | PMC publication ID | 6237027 |
| P698 | PubMed publication ID | 30428932 |
| P50 | author | Becky Skidmore | Q53272564 |
| Chris Cameron | Q88008089 | ||
| P2093 | author name string | Brian Hutton | |
| Christine Brezden-Masley | |||
| Megan E Coombes | |||
| Florence R Wilson | |||
| Abhishek Varu | |||
| Mariya Yurchenko | |||
| Quinlan Wylie | |||
| Reuben Douma | |||
| P2860 | cites work | First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces? | Q26746081 |
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860606 | ||
| Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis | Q28547354 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| GetReal in network meta-analysis: a review of the methodology | Q30251972 | ||
| Incorporating data from various trial designs into a mixed treatment comparison model | Q30594247 | ||
| Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial | Q30758991 | ||
| Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials | Q33293618 | ||
| The importance of adjusting for potential confounders in Bayesian hierarchical models synthesising evidence from randomised and non-randomised studies: an application comparing treatments for abdominal aortic aneurysms | Q33629488 | ||
| Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study | Q33739253 | ||
| Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials | Q33939795 | ||
| Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. | Q33964848 | ||
| Bayesian hierarchical models combining different study types and adjusting for covariate imbalances: a simulation study to assess model performance | Q34053312 | ||
| Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. | Q34484185 | ||
| Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy | Q34743488 | ||
| Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer | Q35038093 | ||
| Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy. | Q35098320 | ||
| Optimal systemic therapy for early breast cancer in women: a clinical practice guideline | Q35239634 | ||
| Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis | Q35496591 | ||
| Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy | Q35580011 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer | Q35742760 | ||
| Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer | Q35847450 | ||
| Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium | Q35915758 | ||
| Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials | Q35947005 | ||
| Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial | Q36102798 | ||
| Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. | Q36253136 | ||
| Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials | Q36387794 | ||
| Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198) | Q36432099 | ||
| HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients | Q36614830 | ||
| Evidence synthesis for decision making 1: introduction | Q36991738 | ||
| Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials | Q37202470 | ||
| Weekly paclitaxel in the adjuvant treatment of breast cancer. | Q37346811 | ||
| Outcomes of her2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients | Q37364604 | ||
| The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine | Q37433324 | ||
| Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). | Q37489864 | ||
| Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial | Q38067005 | ||
| Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation | Q38217011 | ||
| The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations | Q38510678 | ||
| Combining randomized and non-randomized evidence in clinical research: a review of methods and applications | Q38512940 | ||
| St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment | Q38676979 | ||
| Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer | Q38743961 | ||
| Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Ca | Q38811541 | ||
| 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial | Q38953228 | ||
| Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial | Q40166799 | ||
| Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials | Q41822229 | ||
| Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis. | Q42374085 | ||
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response | Q42677733 | ||
| Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients | Q42871099 | ||
| Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer | Q43041241 | ||
| Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials | Q43102818 | ||
| Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall | Q43180234 | ||
| Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial | Q43241014 | ||
| Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial | Q43250043 | ||
| 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. | Q43784378 | ||
| Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial | Q44735204 | ||
| HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results. | Q46682513 | ||
| Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial | Q46764831 | ||
| 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial | Q47973074 | ||
| Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis. | Q51037519 | ||
| Response-guided neoadjuvant chemotherapy for breast cancer. | Q52882601 | ||
| Bias and causal associations in observational research. | Q52936961 | ||
| HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up. | Q53097008 | ||
| Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. | Q53158182 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). | Q53521179 | ||
| Benefit from anthracyclines in relation to biological profiles in early breast cancer. | Q54387195 | ||
| Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. | Q54465171 | ||
| Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. | Q54565799 | ||
| De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 | Q57116621 | ||
| Early breast cancer | Q57142283 | ||
| Indirect Treatment Comparison/Network Meta-Analysis Study Questionnaire to Assess Relevance and Credibility to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report | Q57542840 | ||
| Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool | Q57542870 | ||
| Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort | Q57579888 | ||
| Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q59567316 | ||
| Confounding by indication | Q71502678 | ||
| Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer | Q77924534 | ||
| Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil | Q77995532 | ||
| Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and | Q84368801 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 191 | |
| P577 | publication date | 2018-11-14 | |
| P1433 | published in | Systematic Reviews | Q18216009 |
| P1476 | title | Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis | |
| P478 | volume | 7 |
| Q98625902 | A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation |
| Q91895977 | AK4 Promotes the Progression of HER2-Positive Breast Cancer by Facilitating Cell Proliferation and Invasion |
| Q91974174 | Towards personalized treatment for early stage HER2-positive breast cancer |
Search more.